Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Individualized MicroNutrient Testing for patients

In response to the current trend toward personalized medicine, the Beaumont Weight Control Center, affiliated with Beaumont Hospitals, a major Detroit-area health system, now offers individualized MicroNutrient Testing for patients.

31 Oct 2009

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

The Centers for Disease Control and Prevention (CDC) have classified all children, 6-months to 24-years, one of the high risk groups for contracting the H1N1 (swine) flu, and recommend this population receive the H1N1 vaccine for immunity against the disease.

30 Oct 2009

Soundview Medical Associates chooses Allscripts' EHR and PM for better management

Allscripts announced today that Soundview Medical Associates has selected Allscripts Electronic Health Record (EHR) and Practice Management (PM) to enhance the quality of the care delivered by its 22 physicians, improve patient communications, and better manage the cost of care delivery.

30 Oct 2009

New state-of-the-art biotechnology center opened on the West Coast

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

30 Oct 2009

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

The La Jolla Institute for Allergy & Immunology, an international leader in immunology research and San Diego's only research institute focused solely on immune-mediated diseases, today will dedicate its new Elam Discovery Wall and Type 1 Diabetes Center, which will focus on research into novel immunological-focused approaches to type 1 diabetes.

30 Oct 2009

Online resource to illustrate genetic networks in common autoimmune diseases published

Currently, 5-8% of the U.S. population is afflicted with an autoimmune disease (www.niaid.nih.gov). Many of these are chronic and require life-long care. Moreover, different autoimmune diseases aggregate within a single family, suggesting they are caused by disruptions in common biological pathways.

30 Oct 2009

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

Human Genome Sciences, Inc. today announced financial results for the quarter ended September 30, 2009, and provided highlights of recent key developments.

30 Oct 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

Ipsen announces sales highlights for the first nine months of 2009

Ipsen reported its sales for the third quarter and first nine months of 2009.

29 Oct 2009

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

Today is World Psoriasis Day and the National Psoriasis Foundation is asking all Americans affected by psoriasis and psoriatic arthritis to raise awareness about these diseases by going to www.psoriasis.org/wpd and taking action.

29 Oct 2009

AMT inks agreement with Progenika Biopharma for development of LPLchip

Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.

29 Oct 2009

Steroid-induced osteoporosis can now be treated with Teriparatide

A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate.

29 Oct 2009

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy.

29 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Third-quarter fiscal 2009 results announced by POZEN

POZEN Inc., today announced results for the third quarter ended September 30, 2009.

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Amgen publishes Phase 3 study results of Aranesp

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Individualized MicroNutrient Testing for patients

Data from multiple clinical and preclinical studies evaluating Hematide announced

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

Soundview Medical Associates chooses Allscripts' EHR and PM for better management

New state-of-the-art biotechnology center opened on the West Coast

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

Online resource to illustrate genetic networks in common autoimmune diseases published

Human Genome Sciences declares financial results for third quarter 2009; reports increased revenue growth

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

Ipsen announces sales highlights for the first nine months of 2009

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

AMT inks agreement with Progenika Biopharma for development of LPLchip

Steroid-induced osteoporosis can now be treated with Teriparatide

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Third-quarter fiscal 2009 results announced by POZEN

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in